



To NASDAQ OMX Copenhagen A/S
Announcement No. 16-09 / Copenhagen, 14 May 2009

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com

Interim report for the period 1 January to 31 March 2009

Copenhagen, Denmark – 14 May 2009 - The Board of Directors of TopoTarget A/S (OMX: TOPO) today adopted the company's interim report for the period 1 January to 31 March 2009.

- Sales of Savene[®] and Totect[®] have continued to climb from DKK 7.0 million in Q1 2008 to DKK 11.6 million in Q1 2009. This is an increase from Q1 2008 to Q1 2009 of 66%
- Operating expenses for the three months period ended 31 March 2009 were DKK 42.1 million compared to DKK 60.3 million for the same period 2008
- Operating loss for the three months period ended 31 March 2009 was DKK 29.8 million compared to DKK 50.4 million for the same period 2008
- Loss before tax for the three months period ended 31 March 2009 was DKK 32.9 million compared to DKK 56.7 million for the same period 2008
- Cash, cash equivalent and market securities at 31 March 2009 were DKK 80.8 million compared to DKK 348.0 million at 31 March 2008

Selected milestones met during Q1 2009

- Positive sales growth and profitability reached on Savene[®]/Totect[®]
- Savene[®]/Totect[®] is now being cited as treatment of anthracycline extravasation in nurses guidelines in Europe as well as in the US
- Positive update of initial phase II study with belinostat in PTCL and CTCL which supports registration plan in PTCL
- Initiation of phase II portion of NCI sponsored study with belinostat given at a higher than usual dose for liver cancer
- Positive data with belinostat and 5-FU for gastrointestinal cancer and the possibility to select responding patients presented at ASCO, GI
- Belinostat moved into its first randomized trial in combination with 5-azacytidine in NCI sponsored study in AML and MDS

Highlights for the period after 31 March 2009

- First patient dosed in randomized phase II study of BelCaP (belinostat + carboplatin + paclitaxel) versus carboplatin/paclitaxel in solid tumour indication (CUP)

EGM – Plans for Rights Issue

The Company's Board of Directors has today resolved to convene an Extraordinary General Meeting to be held on 27 May 2009 at which a proposal will be made for the Board of Directors to be authorized by the shareholders to increase the share capital by up to 66,304,510 new shares.

Conference call

TopoTarget will host a conference call this afternoon, 14 May at 2.00 pm (CET), at which management will present and discuss the results for Q1 2009 in English. A presentation will be available on TopoTarget's website, www.topotarget.com, before the start of the conference call.

To participate in the conference call please dial:

- From Denmark: 70 26 50 40
- Outside Denmark: +45 70 26 50 40 or +44 208 817 9301 (UK) or +1 718 354 1226 (US)

A replay of the conference call will be available approximately two hours after the conference call and until 18 August, 2009 at 5.00 pm (CET) at the following number: +353 1 436 4267, pin code: 1666 758#.


Management's report

Savene®/Totect®:

Positive sales growth and profitability reached on Savene®/Totect®

Sales of TopoTarget's first marketed product, Savene®/Totect®, continue to rise. In 2008, we were close to doubling our sales from DKK 21.9 million to DKK 39.1 million relative to 2007.

Sales have continued to climb from DKK 7.0 million in Q1 2008 to DKK 11.6 million in Q1 2009, an increase of 66%. Since late 2008 Savene®/Totect® have traded profitably.



Approval of Totect® by the FDA is now cited in nurses guidelines

Savene® is in EONS (European Oncology Nurses Society) guidelines and Totect® is cited in nursing guidelines for the treatment of anthracycline extravasation in the US.

Savene[®]/Totect[®] has received much publicity and support among healthcare professionals after it was launched. The widespread support is reflected for example in journals, which include an increasing number of articles about Savene[®] and Totect[®]. The value of Savene[®]/Totect[®] is also reflected in the increasing sales of the product.

Belinostat clinical trial progress:

PTCL and CTCL - belinostat monotherapy

On March 16, 2009, a positive update of an initial phase II study with belinostat (monotherapy 1000 mg/m²/daily for 5 days every 3-weeks) in peripheral T-Cell lymphoma (PTCL) and cutaneous T-Cell lymphoma (CTCL) was announced. The study update was presented at an international T-cell lymphoma meeting in Bologna, Italy, March 16-18, and the achieved efficacy and safety data supports the registration plan in PTCL.

The data included an assessment of all treated patients, albeit preliminary since patients are still on treatment and in follow-up. The study has finalized recruitment with 53 patients treated. Initial data from this study led TopoTarget to initiate its pivotal study in PTCL in December 2008 following a Special protocol Assessment (SPA) procedure and Fast Track agreement with the FDA.

Liver cancer - belinostat monotherapy

On January 8, 2009, it was announced that belinostat can be safely administered at higher doses than previously applied in the standard belinostat day 1-5 schedule. A phase I study including patients with previously untreated hepatocellular (liver) cancer being conducted by the Cancer Therapeutic Research Group (CTRG) and sponsored by the Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI, US) has been completed. The phase II portion using belinostat as a single agent to be given in doses of 1400 mg/m²/day, days 1-5 every 3 weeks has started. The most frequent dose previously used in the day 1-5 schedule is 1000 mg/m²/day – this is the regime where belinostat has demonstrated effect in cancer patients suffering both from solid- and haematological diseases. The NCI has initiated the phase II portion of the trial at sites in Hong Kong, Korea, Australia and the US.

The patients in the study suffer from hepatocellular carcinoma (HCC) which is a common cause of cancer morbidity and mortality. It is a highly aggressive tumour with 90% presenting with unresectable disease, resulting in a median survival of 3-6 months. Inhibitors of histone deacetylase (HDAC), including belinostat (Ma B et al, Invest New Drugs, published on line January 27, 2009), have been demonstrated in HCC pre-clinical models to induce apoptosis and tumour regression, and have anti-proliferative, anti-metastatic and anti-invasive effects.

Gastrointestinal cancer - belinostat in combination with 5-FU

On January 15-17, 2009, positive data from a phase Ib study with belinostat and 5-fluorouracil (FU) for patients with solid tumours (majority colorectal cancer) was presented at the ASCO Gastrointestinal Cancers Symposium. The study has established that belinostat and 5-FU can be safely given together at adequate doses. Of 35 patients who have received several earlier treatments (median of 3 prior regimens; majority of patients treated with 2 or more FU-based regimens) nine (26%) obtained stabilisation of their disease. Preclinical studies indicate synergy between belinostat and 5-FU assumed to be due to belinostat down-regulation of thymidylate synthase (TS; main target of 5-FU) and this clinical study supports this assumption by showing TS down-regulation in patients' blood and cancer tissue during belinostat administration. Based on the impact of belinostat on markers (e.g. TS) measurable in patients' blood an algorithm to select patients with the highest probability of a favourable clinical outcome on treatment with belinostat in combination with 5-FU was also presented.

Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukaemia (AML) - belinostat in combination with 5-azacytidine

On January 6, 2009, it was announced that belinostat has moved into the randomized portion of a study in patients with hematologic malignancies where patients with Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukaemia (AML) are treated. Patients will receive treatment with belinostat + 5-azacytidine (experimental group) or 5-azacytidine monotherapy (control group). The study is sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI, US) under a Clinical Trials Agreement with TopoTarget for the development of belinostat.

After the period:

Cancer of Unknown Primary Site - BelCaP (belinostat in combination carboplatin and paclitaxel)

First patient has been dosed in an open label randomized phase II study of belinostat in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated CUP. The study aims to demonstrate the efficacy of belinostat in solid tumours in a randomized setting. Approximately 44 patients will be randomized to each group, in total 88 patients. This was announced on April 16, 2009.

Expected key milestones for 2009 and 2010

- Belinostat deal activities are ongoing and are supported by a steadily growing number of data on belinostat efficacy alone and in combination with successful drugs
- The PTCL phase III registration study will recruit patients during the whole of 2009 and 1H 2010 to obtain the 120 treated patients. An interim analysis is expected when 41 evaluable patients have been recruited
- The CUP randomized phase II study will continue to include patients the whole 2009 and 1H 2010
- The ovarian cancer data in platinum resistant patients is expected to lead to follow up studies in collaboration with NCI and GOG. At ASCO 2009 in June there will be belinostat data from 129 patients. Belinostat oral (tablet) phase I data (doses and safety data) from 3 different schedules will be presented – the use of belinostat IV and as a tablet adds exceptional flexibility to the drug. ASCO 2009 will also present phase II data from a NCI study on belinostat alone in thymoma/thymic carcinoma patients – this study is supported by a good pre-clinical rationale and positive activity seen in a thymoma patient already in phase I
- Other important NCI studies that are expected to be reported is phase II belinostat alone in hepatocellular carcinoma (liver cancer) using high belinostat dosing of 1400 mg/m² for 5 days every 3 weeks and randomized phase II study with 5 azacitidin with or without belinostat in MDS patients. Normal dosing is 1000 mg/m² for 5 days every 3 weeks
- The company expects updates at relevant conferences on phase II BelCaP data with longer follow up data in relapsing ovarian cancer patients including platinum resistant patients and on phase II data including long term remissions in PTCL and CTCL patients
- The company expects to present more data on the ability to identify the belinostat benefitting patients based on the belinostat impact on the gene expression profile in a blood test of patients white blood cells.

Extraordinary General Meeting – Plans for Rights Issue - Expressions of Interest from Third Parties

The Company's Board of Directors has today as earlier announced resolved to convene an Extraordinary General Meeting to be held on 27 May 2009. At the Extraordinary General Meeting, the Board of Directors will propose that the Board of Directors be authorized by the shareholders to increase the Company's share capital by up to 66,304,510 new shares. It is contemplated that the authorization will be utilized in the form of a fully tradeable rights issue to existing shareholders as soon as practically possible and expectedly during Q2 or Q3 2009. Through the rights issue, the Board of Directors seeks to strengthen the Company's financial position generally and aims to strengthen the Company's possibilities for reaching a value-enhancing partnering agreement on belinostat with a strong partner as well as to obtain financing for the achievement of the Company's key milestones.

In connection with the Company's announcement of its plan to increase the share capital by way of a rights issue, the Board of Directors note that the Company has recently been in contact with certain biotech companies with a view to discuss possible future cooperation opportunities. The Company has in this connection received a preliminary, indicative non-binding suggestion for a combination with another listed foreign company in the form of a proposal for a share-for-share deal (share swap) with TopoTarget shares being exchanged for shares in the said company on the basis of an estimated price level which percentage-wise is significantly higher than the current (listed) market price of TopoTarget's shares.

This preliminary, indicative approach is subject to various provisions and conditions and on the basis of an initial analysis and assessment of the proposal, the Board of Directors does not consider the approach as being sufficiently attractive at the current stage. The Company intends to clarify the Company's strategic options, but has decided to continue to pursue the contemplated rights issue which has been discussed with the Company's financial advisers for some time.

A formal notice convening the Extraordinary General Meeting containing the agenda and the full text of the proposals will be made public by a separate company announcement to be released immediately following this company announcement.

Statement by the Board of Directors and Senior Management

The Board of Directors and Senior Management today discussed and adopted the interim report for TopoTarget for the 3 months ended 31 March 2009.

The interim report is presented in accordance with IAS 34 as adopted by EU and additional Danish disclosure requirements on the presentation of interim reports by listed companies. The interim report is not audited or reviewed.

We consider the accounting policies to be appropriate. Accordingly, the interim report gives a true and fair view of the Group's assets, liabilities, and financial position at 31 March 2009 and of Group's operations and cash flows for the 3 months ended 31 March 2009.

In our opinion, the management's report gives a true and fair view of developments in the activities and financial position of the Group, the results for the period and of the Group's financial position in general and gives a fair description of significant risk and uncertainty factors that may affect the Group.

Copenhagen, 14 May 2009

Senior Management

Peter Buhl Jensen
CEO

Board of Directors

Håkan Åström
Chairman

Jesper Zeuthen

Jeffrey Buchalter

Anders Gersel Pedersen

Ingelise Saunders

Torbjørn Bjerke

Peter Buhl Jensen

Highlights and key figures

Consolidated income statements	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Revenues	12,343	9,917	43,890
Production costs	(2,230)	(4,332)	(10,082)
Research and development costs	(24,489)	(29,546)	(146,906)
Write down of research and development projects	0	0	(93,500)
Sales and distribution costs	(9,275)	(13,085)	(44,796)
Administrative expenses	(6,108)	(13,333)	(42,977)
Financial income and expenses	(3,104)	(6,297)	(11,737)
Loss before tax	(32,863)	(56,676)	(306,107)
Basic and diluted EPS (DKK)	(0.46)	(0.89)	(4.68)

Consolidated balance sheets	31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	31 December 2008 DKK ' 000
Cash and cash equivalents and marketable securities	80,823	348,024	107,998
Assets	564,052	776,964	619,032
Equity	400,358	612,837	429,376

Consolidated cash flow statements	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Cash flows from operating activities	(27,541)	(54,525)	(169,544)
Cash flows from investing activities	35,785	(4,651)	(44,366)
Cash flows from financing activities	(124)	(121)	(499)

Consolidated key figures	31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	31 December 2008 DKK ' 000
Number of fully paid shares in issue as at period end	66,304,510	61,304,510	61,304,510
Weighted average number of shares in issue for the period	66,304,510	61,304,510	53,955,186
Assets/equity	1.41	1.27	1.44
Share price, closing (DKK)	2.52	10.30	3.62
Share price, book value (DKK)	6.04	10.00	7.00
Average number of employees	60	135	109

Comments on the interim financial statements for the three months ended 31 March 2009

With effect from April 2008 TopoTarget reacquired total control over the company's lead project belinostat. Due to the uncertainty generated by recent financial turbulence, TopoTarget undertook a significant restructuring and focusing of the company during the course of 2008 to ensure its existing financial resources lasted into the beginning of 2010. This resulted in a reduction of our work force and the development of belinostat being the primary focus of the company. Pre-clinical

activities were cut to what is required to support the belinostat clinical development and form the basis of re-growth once belinostat has been outlicensed.

Management expects that during the course of 2009 a funding event will occur that will enable continued development of belinostat into 2011 and that during this time a licensing or similar type agreement in respect of belinostat will be entered into that will enable continued development of belinostat and other programmes in 2011 and beyond. Consequently TopoTarget has prepared its financial statement on a going concern basis. Management acknowledge that there are some risks associated with this strategy which are set out under Accounting Policies in note 1 of this interim financial statements including in relation to the value of research and development projects acquired from third parties.

The company generated revenue of DKK 12.3 million during the period compared with DKK 9.9 million in the same period last year. Included in revenues in 2009 are sales of Savene[®] in Europe and sales of Totect[®] in the US along with a small amount of other income. In 2008 revenues included both sales of Savene[®] and Totect[®] as well as income from the CuraGen collaboration.

The sales of Savene[®] in Europe and Totect[®] in the US increased significantly in Q1 2009 to DKK 11.6 million compared to Q1 2008, which were DKK 7.0 million. The other income in Q1 2009, DKK 0.8 million, arises from a sublease in the Swiss subsidiary. In Q1 2008 there was DKK 2.9 million revenue derived from reimbursement of research and development costs to CuraGen however the CuraGen collaboration ended with TopoTarget purchasing back global rights in April 2008 thus there was no comparable revenue from this source in Q1 2009.

In the first three months of 2009, production costs amounted to DKK 2.2 million as compared with DKK 4.3 million in the same period of 2008, the latter included expenditure to be reimbursed by CuraGen. The reduction is primarily due to the aforementioned cessation of the CuraGen collaboration.

In the period 1 January to 31 March 2009, research and development costs amounted to DKK 24.5 million as compared with DKK 29.6 million in the same period of 2008. This reduction was primarily due to the Company's restructuring in 2008 making belinostat the Company's primary focus along with finalising one study with APO866 and leading to reductions in both internal staff costs and external CRO costs.

First-quarter sales and distribution costs amounted to DKK 9.3 million, down from DKK 13.1 million in the same period of 2008. The reduction is due to the finalisation of the initial launch-phase of Totect[®] in the US and the restructuring and reprioritising of territories in the US and Europe.

In the period 1 January to 31 March 2009, administrative expenses amounted to DKK 6.1 million as compared with DKK 13.3 million in the same period of 2008. The reduction can be attributed primarily to the restructuring of internal resources in line with the company's focus on belinostat.

Net financial expenses amounted to DKK 3.1 million in the first three months, as compared with net financial expenses of DKK 6.3 million in the same period of 2008. The difference is primarily due to lower currency translation differences on consolidation of group enterprises in 2009 compared to 2008.

In the period 1 January to 31 March 2009, the company recorded a loss before tax of DKK 32.9 million as compared with a loss before tax of DKK 56.7 million in the same period of 2008.

In the first three months of 2009 there was a tax income of DKK 2.3 million compared with a tax income of DKK 1.9 million in the same period of 2008, both resulting from a reduction in the deferred tax liability concerning TopoTarget Switzerland S.A.

In the period 1 January to 31 March 2009, the company recorded a loss after tax of DKK 30.6 million as compared with a loss after tax of DKK 54.8 million in the same period of 2008.

Acquired research and development projects as at 31 March 2009 amounted to DKK 453.0 million, compared to DKK 370.3 million as at 31 March 2008. The change primarily relates to the acquisition of belinostat rights in April 2008 (DKK 209 million) and the write down of some existing projects end 2008 (DKK 93.5 million).

Consequently, the value of acquired research and development projects recognised in the balance sheet as at 31 March 2009 primarily consist of the following projects; belinostat programme acquired in conjunction with the acquisition of TopoTarget UK in 2002 and in April 2008 in conjunction with the purchase from the former American partner to obtain the full control of this programme as well as APO010 and APO866 acquired in conjunction with the acquisition of TopoTarget Switzerland S.A. in 2007. If timely and adequate financing as assumed cannot be obtained, TopoTarget may be required to significantly curtail its clinical development activities, which could lead to a loss in value of research and development recognised in the balance sheet as at 31 March 2009.

At 31 March 2009, total assets amounted to DKK 564.1 million. Of this amount, cash and cash equivalents amounted to DKK 80.8 million.

At 31 March 2009, equity amounted to DKK 400.4 million compared with DKK 612.8 million at the same time in 2008. The change consists of a loss of DKK 277.1 million during the period from 1 April 2008 to 31 March 2009, the capital increase in May 2008 totalling DKK 55.5 million, additions during the period of share-based payment totalling DKK 9.2 million and fair value adjustment of the bond portfolio totalling DKK 0.2 million.

Outlook for 2009

The company retains its full-year 2009 guidance, announced in connection with the Annual Report 2008, for a pre-tax loss in the range of DKK 120 million to DKK 140 million. As in previous years the forecast includes non-cash items such as depreciation and warrant accrual costs. The forecast is based on management's objective of ensuring that current financial resources take it into the beginning of 2010 without any funding events such as belinostat license or capital raise. Management expects that during the course of 2009 a funding event will occur that will enable continued development of belinostat into 2011 and that during this time a licensing or similar type agreement in respect of belinostat will be entered into that will ensure the company is a going concern and enable continued development of belinostat and other programmes in 2011 and beyond. Such an event will affect the Company's pre-tax loss for the year and TopoTarget will at that time amend its forecast and advise the market accordingly.

TopoTarget A/S

For further information, please contact:

Peter Buhl Jensen
CEO

Telephone +45 39 17 83 92
Mobile +45 21 60 89 22

Background information

About TopoTarget

TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. The company was founded and is run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer.

TopoTarget has a broad clinical pipeline but is currently focusing on the development of belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours where it can be used in combination with full doses of chemotherapy, and is in phase III in

PTCL. TopoTarget's expertise in translational research is utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget is directing its efforts on key cancer targets including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors. The company's first marketed product Savene[®]/Totect[®] was approved by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales force in Europe and the US. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Condensed income statements

	Note	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Revenue	2,3	12,343	9,917	43,890
Production costs	4	(2,230)	(4,332)	(10,082)
Research and development costs	4,5	(24,489)	(29,546)	(146,906)
Write down of research and development projects		0	0	(93,500)
Sales and distribution costs	4	(9,275)	(13,085)	(44,796)
Administrative expenses	4	<u>(6,108)</u>	<u>(13,333)</u>	<u>(42,977)</u>
Operating loss		(29,759)	(50,380)	(294,370)
Financial income and expenses		<u>(3,104)</u>	<u>(6,297)</u>	<u>(11,737)</u>
Loss before taxes		(32,863)	(56,676)	(306,107)
Tax on profit/(loss) for the period		<u>2,277</u>	<u>1,849</u>	<u>4,899</u>
Net loss for the period		<u>(30,586)</u>	<u>(54,828)</u>	<u>(301,208)</u>
Basic and diluted EPS (DKK)		(0.46)	(0.89)	(4.68)

Condensed consolidated comprehensive income for the period

	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Net loss for the period	(30,586)	(54,828)	(301,208)
Fair value adjustment of available-for-sale financial assets Transferred to income statement concerning value	0	227	227
adjustment of available-for-sale financial assets	0	(19)	(227)
Income tax relating to components of other comprehensive income	<u>0</u>	<u>0</u>	<u>0</u>
Other comprehensive income for the period (net of tax)	<u>0</u>	<u>208</u>	<u>0</u>
Total comprehensive income for the period	<u>(30,586)</u>	<u>(54,620)</u>	<u>(301,208)</u>

Condensed balance sheets - assets

	Note	31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	2008 DKK ' 000
Intangible assets	5	452,953	370,264	467,381
Property, plant and equipment		10,634	17,637	12,094
Non-current investments		<u>1,608</u>	<u>1,910</u>	<u>1,923</u>
Non-current assets		<u>465,194</u>	<u>389,811</u>	<u>481,398</u>
Inventories		2,612	2,632	2,566
Receivables		15,423	36,497	27,070
Securities	6	0	120,208	35,295
Cash and cash equivalents		<u>80,823</u>	<u>227,816</u>	<u>72,703</u>
Current assets		<u>98,858</u>	<u>387,153</u>	<u>137,634</u>
Assets		<u><u>564,052</u></u>	<u><u>776,964</u></u>	<u><u>619,032</u></u>

Condensed balance sheets - equity and liabilities

	Note	31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	2008 DKK ' 000
Equity		<u>400,358</u>	<u>612,837</u>	<u>429,376</u>
Non-current liabilities	7	121,676	52,150	105,875
Current liabilities	8	<u>42,018</u>	<u>111,976</u>	<u>83,781</u>
Liabilities		<u>163,694</u>	<u>164,126</u>	<u>189,656</u>
Equity and liabilities		<u><u>564,052</u></u>	<u><u>776,964</u></u>	<u><u>619,032</u></u>
Accounting policies	1			

Condensed cash flow statements

	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Operating loss	(29,759)	(50,380)	(294,370)
Reversal of share-based payments	1,569	2,389	10,015
Reversal of pension commitments	0	0	(1,838)
Depreciation, amortisation and impairment losses	1,644	2,056	101,438
Working capital changes	(6,112)	(7,165)	9,191
Cash flows from operating activities before interest	(32,659)	(53,100)	(175,564)
Received and paid interest etc.	5,117	(1,425)	6,020
Cash flows from operating activities	(27,542)	(54,525)	(169,544)
Purchase of intangible assets	0	0	(125,474)
Purchase of property, plant and equipment	(0)	(903)	(1,158)
Sale of property, plant and equipment	175	0	1,322
Purchase of investments	315	(253)	(266)
Purchase of securities	0	(49,125)	(84,420)
Sale of securities	35,295	45,631	165,630
Cash flows from investing activities	35,785	(4,651)	(44,366)
Instalment on loans	(124)	(121)	(499)
Cash flows from financing activities	(124)	(121)	(499)
Increase/decrease in cash and cash equivalents	8,120	(59,297)	(214,409)
Cash and cash equivalents at 1 January	72,703	287,112	287,112
Cash and cash equivalents at 31 March	80,823	227,815	72,703
Cash and cash equivalents comprise:			
Deposit on demand and cash	80,778	227,815	72,580
Special-term deposits	45	0	123
Total	80,823	227,815	72,703

Statement of equity for the period 1 January to 31 March 2009

	Number of shares	Share- capital DKK ' 000	Share- based payments DKK ' 000	Retained earnings DKK ' 000	Total DKK ' 000
Equity at 1 January 2009	66,304,510	66,304	27,347	335,725	429,376
Recognition of share-based payment	0	0	1,569	0	1,569
Total comprehensive income for the period	0	0	0	(30,586)	(30,586)
Equity 31 March 2009	66,304,510	66,304	28,916	305,138	400,358

The share capital is an undistributable reserve, while the other reserves are distributable for dividend purposes subject to the provisions of the Danish Public Companies Act.

Statement of equity for the period 1 January to 31 March 2008

	Number of shares	Share- capital DKK ' 000	Share- based payments DKK ' 000	Retained earnings DKK ' 000	Total DKK ' 000
Equity 1 January 2008	61,304,510	61,304	17,332	586,432	665,068
Recognition of share-based payment	0	0	2,389	0	2,389
Total comprehensive income for the period	0	0	0	(54,620)	(54,620)
Equity 31 March 2008	61,304,510	61,304	19,721	531,812	612,837

The share capital is an undistributable reserve, while the other reserves are distributable for dividend purposes subject to the provisions of the Danish Public Companies Act.

Notes to the consolidated interim financial statements

1. ACCOUNTING POLICIES

The interim financial statements have been prepared in accordance with IAS 34, Interim financial reporting, and additional requirements for interim financial statements of listed companies. No interim financial statements have been prepared for the parent company.

The accounting policies applied in the interim report are unchanged relative to the accounting policies applied in the company's annual report for 2008, and are in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU and additional Danish disclosure requirements for annual reports of listed companies.

The interim report is presented in Danish kroner (DKK), which is the parent company's functional currency.

Management's significant accounting assumptions and estimates

Going Concern statement

TopoTarget's financial statements are prepared on a going concern basis. Management is running the company to a budget with the objective of ensuring that current financial resources take it into the beginning of 2010. Management expects that during the course of 2009 a funding event will occur that will enable continued development of belinostat into 2011 and that during this time a licensing or similar type agreement in respect of belinostat will be entered into that will enable continued development of belinostat and other programmes in 2011 and beyond. Management acknowledges that there are some risks associated with this strategy which include the following:

- The budget assumes a net profit for the year from sales of its marketed product Savene[®]/Totect[®]. While management is confident of achieving such profit there is a risk that the necessary sales to produce a profit will not be met, reducing the Company's runway;
- While management is also confident of entering into a licensing or similar type deal on belinostat during the course of 2009, if it is not achieved in a timely manner, TopoTarget may be required to seek additional financing by way of equity issue or similar, which may not be available when required, or at all;
- Alternatively, if the Company is successful in raising additional funds by issuing equity securities, the value of shares then held by investors may be diluted;
- If additional financing is not available the Company could be required to seek funds through sale or out-licensing arrangements that may involve relinquishing rights to the Company's technologies, candidate drugs or products the Company would prefer to keep or develop on its own;
- If timely and adequate financing cannot be obtained, the Company may be required to significantly curtail its clinical development activities, which could lead to a loss in value of its research and development projects including those that have been previously acquired from third parties and are recognized on the Company's balance sheet;

Impairment test of acquired research and development projects

In the period until a marketing approval has been obtained, the acquired research and development project is tested for impairment annually. After marketing approval has been obtained, an impairment test is performed only where events or other circumstances indicate that the carrying amount may not be recoverable.

Acquired research- and development projects recognized in the balance sheet as at 31 March 2009 amounts to DKK 453.0 million primarily related to belinostat, APO010 and APO866.

On the basis of TopoTarget's current financial reserves it is assumed that during the course of 2009 a funding event will occur that will enable continued development of belinostat into 2011 and that during this time a licensing or similar type agreement in respect of belinostat will be entered into that will enable continued development of belinostat and other programmes in 2011 and beyond. If timely and adequate financing cannot be obtained, TopoTarget may be required to significantly curtail its clinical development activities, which could lead to a loss in value of research and development recognised in the balance sheet as at 31 March 2009.

Calculation of payable part of consideration for TopoTarget Switzerland S.A. (formerly Apoxis S.A.) and belinostat rights

In June 2007, TopoTarget acquired the company Apoxis S.A. (now TopoTarget Switzerland S.A.). Part of the consideration consisted of a milestone payment (APO866 milestone), the payment of which is contingent upon the occurrence of certain events. Based on management's assessment of the circumstances which the milestone payments are contingent upon, the considerations at acquisition was calculated on the basis of an estimate that the value in use of APO866 milestone could be calculated at DKK 61.7 million.

In April 2008, TopoTarget reacquired total control over belinostat from its former business partner CuraGen. The purchase price consisted of a commercial milestone payment totalling USD 6 million (approximately DKK 28.3 million), which was defined as 10% of the first USD 60 million of TopoTarget's income from sales or partnership revenue concerning belinostat.

Based on project development, these calculations have subsequently been revised compared with the original calculation, causing a reduction of the obligations and a corresponding adjustment of acquired ongoing research and development projects. The estimated obligations may be adjusted further, depending on whether and when the payment criteria are met.

Revised standards and interpretations

The following new and revised standards and interpretations are effective from the financial year 2009:

- IAS 1, Presentation of financial statements
- IFRS 8, Operating segments
- IAS 23, Borrowing costs
- IAS 27, Consolidated and separate financial statements
- IFRS 1, First-time adoption of international financial reporting standards
- IAS 32, Financial instruments: Presentation
- IFRS 2, Share-based payments
- IFRS 7, Financial instruments: Disclosures
- IFRIC 13, Customer loyalty programmes
- IFRIC 15, Agreements for the construction of real estate
- IFRIC 16, Hedges of a Net Investment in a Foreign Operation

The implementation of the new and revised standards and interpretations in the interim report for Q1 2009 has not resulted in changes to accounting policies except for the further disclosure requirements that follow from the standards.

2. REVENUE

	3 months 2009 DKK '000	3 months 2008 DKK '000	2008 DKK '000
Sales of goods	11,549	7,006	39,139
Sales of services	793	2,911	4,229
Milestone payments	0	0	522
Total	12,343	9,917	43,890

3. SEGMENT INFORMATION

Primary segments

The Group's activities are exclusively in the business segment "Pharmaceuticals for treatment within the cancer area"

Secondary segments

The Group's revenue is divided into the following secondary geographical segments:

	Revenue		
	3 months 2009 DKK '000	3 months 2008 DKK '000	2008 DKK '000
Denmark	291	218	1,237
Europe	6,640	4,487	21,646
USA	5,411	5,212	21,007
Total	12,343	9,917	43,890

The Groups assets and additions to licences and rights plus other fixtures and fittings, tools and equipment are divided into the following secondary geographical segments:

	Assets		Additions to aquired research & development projects plus other fixtures and fittings, tools and equipment			
	31 March 2009 DKK '000	31 March 2008 DKK '000	2008 DKK '000	3 months 2009 DKK '000	3 months 2008 DKK '000	2008 DKK '000
Denmark	307,074	397,213	356,597	0	580	210,045
Europe	247,632	375,320	252,684	0	323	188
USA	9,346	4,430	9,752	0	0	481
Total	564,052	776,964	619,032	0	903	210,714

4. STAFF COSTS

	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Allocated by function:			
Production costs	0	326	195
Research and development costs	6,599	14,031	56,778
Sales and distribution costs	5,343	5,432	22,090
Administrative expenses	2,689	7,541	23,597
Total	14,631	27,330	102,660
Hereof share-based payments	1,568	2,389	10,015
Average number of employees	60	135	109

5. INTANGIBLE ASSETS

	31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	2008 DKK ' 000
Acquired research- and development projects still in progress			
Cost at 1 January	455,680	357,438	357,438
Adjustment of acquisition value	(14,053)	0	(17,534)
Addition by acquisition of subsidiary	0	0	0
Additions	0	0	209,276
Disposals	0	0	0
Cost at 31 March	441,627	357,438	549,180
Amortisation 1 January	0	0	0
Amortisation and write downs	0	0	(93,500)
Amortisation at 31 March	0	0	(93,500)
Carrying amount at 31 March	441,627	357,438	455,680
Acquired research- and development projects - available for use			
Cost at 1 January	15,076	15,076	15,076
Cost at 31 March	15,076	15,076	15,076
Amortisation at 1 January	(3,375)	(1,875)	(1,875)
Amortisation	(375)	(375)	(1,500)
Amortisation at 31 March	(3,750)	(2,250)	(3,375)
Carrying amount at 31 March	11,326	12,826	11,701
The weighted average residual term of acquired research and development projects - available for use is approximately (number of years)	7.50	8.50	7.75
Total acquired research and development projects	452,953	370,264	467,381
Amortisation and impairment by function:			
	3 months 2009 DKK ' 000	3 months 2008 DKK ' 000	2008 DKK ' 000
Production costs	375	375	1,500

6. SECURITIES

Securities comprise:

		31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	2008 DKK ' 000
Callable loans	DKK	0	68,230	35,295
Non callable loans	DKK	0	51,978	0
Total		0	120,208	35,295
Securities expire:				
Up to 1 year		0	5,193	35,295
One to five years		0	29,848	0
More than five years		0	85,167	0
Total		0	120,208	35,295

All bonds are mortgage or government bonds with low risk and a fixed nominal interest of nominal 4% p.a. in 2008. All bonds are paid in full at 2 January 2009.

7. NON-CURRENT LIABILITIES

		31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	2008 DKK ' 000
Deferred income tax		43,259	49,097	46,095
Lease commitments		0	314	0
Pension commitments		751	2,739	761
Other debt		77,665	0	59,019
Total		121,676	52,150	105,875

Other debt is primarily debt in relation to the APO866-milestone and the belinostat-milestone. The belinostat-milestone has been reclassified from current liabilities in 2008 as it is assessed that the due date is later than 12 months from the balance sheet date.

8. CURRENT LIABILITIES

	31 March 2009 DKK ' 000	31 March 2008 DKK ' 000	2008 DKK ' 000
Leasing commitments	191	378	315
Trade payables	35,304	33,218	42,811
Other payables	6,523	75,314	40,655
Deferred income	0	3,066	0
Total	42,018	111,976	83,781

Other debt in the comparison year at 31 March 2008
is primarily debt in relation to the APO866-milestone.